SCHEMBL4683591

SCHEMBL4683591

CC1(C)CCc2nc(-c3cc(-c4cccc(F)c4)nn3-c3cccc(F)c3)ccc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.38
HSD11B1 P28845 3/20 0.35
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 3/20 0.34
USP2 O75604 2/20 0.34
MAPT P10636 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
AHR P35869 1/20 0.34
NR3C2 P08235 1/20 0.33
SLC5A1 P13866 1/20 0.33
KDM4E B2RXH2 2/20 0.33
GUSB P08236 1/20 0.33
LMNA P02545 1/20 0.33
CDC7 O00311 1/20 0.32
PIM1 P11309 1/20 0.32
GSK3B P49841 1/20 0.32
HIPK2 Q9H2X6 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4684302 0.95 GRM5 (0.41) GRM5HSD11B1ALDH1A1HPGDMAPT
SCHEMBL4742814 0.86 GRM5 (0.47) GRM5ALDH1A1HPGDHSD17B10MAPT
SCHEMBL13707004 0.85 GRM5 (0.47) GRM5MAPTKDM4E
SCHEMBL4685631 0.83 CYP2C19 (0.41) ALDH1A1HPGDCDC7PIM1GSK3B
SCHEMBL4680574 0.82 GRM5 (0.41) GRM5ALDH1A1HPGDHSD17B10USP2
SCHEMBL4683224 0.82 GRM1 (0.42) GRM5MAPTKDM4E
SCHEMBL4686026 0.80 USP8 (0.42) GRM5MAPTKDM4E
SCHEMBL4678329 0.80 USP8 (0.44) GRM5MAPTKDM4E
SCHEMBL4682564 0.79 GRM5 (0.37) GRM5HSD11B1HSD17B10USP2TSHR
SCHEMBL4683105 0.78 TP53 (0.42) GRM5ALDH1A1HPGDSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US claimed
EP-1943247-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Merz Pharma GmbH & Co.KGaA (DE) 2008-07-16 EP disclosed
WO-2007023245-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-03-01 WO disclosed
WO-2007023245-A1 TETRAHYDROQUINOLINONES AND THEIR USE AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2007-03-01 WO disclosed
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors MERZ PHARMA GMBH & CO., KGAA (DE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004001-A1 Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors GRM1, GRM5, GRM2 GRM5 2/4885HSD11B1 2917/4885ALDH1A1 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.